JEFFERSON, N.C., Dec. 19 /CNW/ -- Next Safety, Inc., a leader in
developing pulmonary drug delivery devices, today announced verification of a
significant breakthrough in pulmonary science that provides high efficacy
delivery of drugs to the lungs.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070615/CLF038LOGO )
Advanced optical characterization techniques performed by a third party
laboratory showed that 99.8% of the droplets delivered by Next Safety's
pulmonary drug delivery devices were between one and three microns in
diameter, and the droplets separated sufficiently in space and time to be
absorbed into the alveoli of the lungs.
The company has already demonstrated more rapid delivery of nicotine to
the bloodstream through the lungs than possible with cigarettes.
Next Safety's advance means that:
-- Drugs previously restricted to intravenous or oral delivery such as
antibiotics, analgesics, anti-emetics, peptides and proteins like
insulin and vaccines can be delivered to the human body directly
through the lungs.
-- The pharmaceutical industry can offer medications with systemic
delivery without needles, syringes and intravenous lines.
Four of the ten largest global pharmaceutical companies have expressed
interest in the company's pulmonary business. Next Safety expects to begin a
bidding process for its pulmonary business in early 2008.
Next Safety's immediate and ongoing research studies focus on the
pulmonary delivery of nicotine, albuterol, tobramyacin and long chain peptide
and protein molecules. Nicotine delivery and other clinical findings from
brain imaging and arterial blood studies conducted in partnership with a major
U.S. medical institution will be announced in the first quarter of 2008.
"Previous nicotine replacement products have helped millions of smokers
worldwide. However the delivery mechanisms of these products cannot equal the
power of nicotine delivered through the smoked cigarette. The next step in
nicotine replacement treatment is the ability to deliver nicotine directly to
the lung and brain, in the same manner as a cigarette, without the 4,000
harmful chemicals in tobacco" said Matthew Bars, MS, CTTS, an expert in
nicotine addiction, key opinion leader and consultant to the pharmaceutical
industry and Next Safety, Inc. Mr. Bars is the Director of the New York City
Fire Department's Tobacco Cessation Program. "Pulmonary delivery of 'clean'
nicotine would become the gold standard of nicotine replacement therapies. The
Next Safety pulmonary nicotine delivery device has the potential of saving the
lives of hundreds of millions of smokers worldwide" Bars concluded.
For more information about Next Safety, Inc. or the bidding process,
please visit our website www.nextsafety.com.
For further information:
For further information: Christy Cheek of Next Safety, Inc.,
+1-336-246-7700, email@example.com Web Site: